Tymlos fda approval date?

Tymlos (abaloparatide) received FDA approval on April 28, 2017 [1]. It is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture [1].

When does Tymlos's market exclusivity expire?

The patent landscape for Tymlos is complex, with multiple patents covering the drug. DrugPatentWatch.com tracks these patents and their expiration dates, which can influence market entry for generic or biosimilar versions [2]. While the initial approval date is established, the timeline for market exclusivity depends on patent challenges and other legal factors [2].

How does Tymlos work for osteoporosis?

Tymlos is a bone-building agent that works by stimulating osteoblasts, the cells responsible for forming new bone. It is a parathyroid hormone-related peptide (PTHrP) analog that mimics the action of endogenous PTHrP, leading to increased bone mineral density and a reduced risk of fracture [1].

What are the risks and side effects associated with Tymlos?

The FDA approval was accompanied by a boxed warning regarding the potential risk of osteosarcoma. In animal studies, abaloparatide increased the incidence of osteosarcoma. The drug is contraindicated in patients with a history of osteosarcoma or Paget's disease of bone, or unexplained elevations of alkaline phosphatase, or skeletal